191 related articles for article (PubMed ID: 34835197)
1. Development of an Inactivated Vaccine against SARS CoV-2.
Pavel STI; Yetiskin H; Uygut MA; Aslan AF; Aydın G; İnan Ö; Kaplan B; Ozdarendeli A
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835197
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A
Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.
Kandeil A; Mostafa A; Hegazy RR; El-Shesheny R; El Taweel A; Gomaa MR; Shehata M; Elbaset MA; Kayed AE; Mahmoud SH; Moatasim Y; Kutkat O; Yassen NN; Shabana ME; GabAllah M; Kamel MN; Abo Shama NM; El Sayes M; Ahmed AN; Elalfy ZS; Mohamed BM; Abd El-Fattah SN; El Hariri HM; Abdel Kader M; Azmy O; Kayali G; Ali MA
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33802467
[TBL] [Abstract][Full Text] [Related]
4. Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa).
Ben Ahmed M; Bellali H; Gdoura M; Zamali I; Kallala O; Ben Hmid A; Hamdi W; Ayari H; Fares H; Mechri K; Marzouki S; Triki H; Ben Alaya N; Chahed MK; Klouz A; Sebai Ben Amor S; Ben Rayana C; Razgallah Khrouf M; Hamouda C; Elkadri N; Daghfous R; Trabelsi A
Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 35893838
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview.
Shiravi AA; Ardekani A; Sheikhbahaei E; Heshmat-Ghahdarijani K
Cardiol Ther; 2022 Mar; 11(1):13-21. PubMed ID: 34845662
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
7. A global survey in the developmental landscape of possible vaccination strategies for COVID-19.
Gasmi A; Srinath S; Dadar M; Pivina L; Menzel A; Benahmed AG; Chirumbolo S; Bjørklund G
Clin Immunol; 2022 Apr; 237():108958. PubMed ID: 35218966
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.
Ophinni Y; Hasibuan AS; Widhani A; Maria S; Koesnoe S; Yunihastuti E; Karjadi TH; Rengganis I; Djauzi S
Acta Med Indones; 2020 Oct; 52(4):388-412. PubMed ID: 33377885
[TBL] [Abstract][Full Text] [Related]
9. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2.
Jamous YF; Alhomoud DA
Cureus; 2023 Sep; 15(9):e45602. PubMed ID: 37868494
[TBL] [Abstract][Full Text] [Related]
10. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
11. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
[TBL] [Abstract][Full Text] [Related]
12. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
Turan RD; Tastan C; Dilek Kancagi D; Yurtsever B; Sir Karakus G; Ozer S; Abanuz S; Cakirsoy D; Tumentemur G; Demir S; Seyis U; Kuzay R; Elek M; Kocaoglu ME; Ertop G; Arbak S; Acikel Elmas M; Hemsinlioglu C; Hatirnaz Ng O; Akyoney S; Sahin I; Kayhan CK; Tokat F; Akpinar G; Kasap M; Kocagoz AS; Ozbek U; Telci D; Sahin F; Yalcin K; Ratip S; Ince U; Ovali E
Sci Rep; 2021 Aug; 11(1):15799. PubMed ID: 34349145
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Review on Various Aspects of SARS-CoV-2 (COVID-19) Vaccines.
Pordanjani SR; Pordanjani AR; Askarpour H; Arjmand M; Babakhanian M; Amiri M; Mazaheri E
Int J Prev Med; 2022; 13():151. PubMed ID: 36911005
[TBL] [Abstract][Full Text] [Related]
15. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.
Doroftei B; Ciobica A; Ilie OD; Maftei R; Ilea C
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33804914
[TBL] [Abstract][Full Text] [Related]
16. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
Wang Y; Yang C; Song Y; Coleman JR; Stawowczyk M; Tafrova J; Tasker S; Boltz D; Baker R; Garcia L; Seale O; Kushnir A; Wimmer E; Mueller S
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34193524
[TBL] [Abstract][Full Text] [Related]
17. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
[TBL] [Abstract][Full Text] [Related]
18. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
[TBL] [Abstract][Full Text] [Related]
19. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models.
Wang ZJ; Zhang HJ; Lu J; Xu KW; Peng C; Guo J; Gao XX; Wan X; Wang WH; Shan C; Zhang SC; Wu J; Yang AN; Zhu Y; Xiao A; Zhang L; Fu L; Si HR; Cai Q; Yang XL; You L; Zhou YP; Liu J; Pang DQ; Jin WP; Zhang XY; Meng SL; Sun YX; Desselberger U; Wang JZ; Li XG; Duan K; Li CG; Xu M; Shi ZL; Yuan ZM; Yang XM; Shen S
Emerg Microbes Infect; 2020 Dec; 9(1):2606-2618. PubMed ID: 33241728
[TBL] [Abstract][Full Text] [Related]
20. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
